lg bekræftet symptomatisk tilbagevendende ikke fatal VTE og fatal VTE indberettet frem til dag 97.
The primary efficacy endpoint was the composite of confirmed symptomatic recurrent non-fatal VTE and fatal VTE reported up to Day 97.